Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gastric Cancer Detected Through Exhaled Breath

By LabMedica International staff writers
Posted on 27 Apr 2015
A new type of technology that senses minute changes in the levels of particular compounds in exhaled breath accurately identifies high risk changes which herald the development of stomach cancer.

The technology, known as nanoarray analysis, could be used not only to test for the presence of stomach cancer, but also to monitor those at high risk of subsequently developing the disease as stomach cancer rarely causes symptoms in its early stages, making it hard to detect.

Scientists at the Israel Institute of Technology (Haifa, Israel;) and their colleagues collected 968 breath samples from 484 patients, including 99 with gastric cancer, for two different analyses. More...
The participants had fasted for 12 hours prior to the breath samples being taken and had refrained from smoking for at least three hours beforehand. In addition, subjects were tested for infection with Helicobacter pylori infection, an established risk factor for stomach cancer, and their smoking and drinking habits were analyzed.

The first sample was analyzed by gas chromatography linked to mass spectrometry (GCMS) and the second by cross-reactive nanoarrays combined with pattern recognition. The GCMS analysis that measures the levels of volatile organic compounds (VOCs) identified 130 VOCs in participants' exhaled breath. On comparing the breath samples of participants with stomach cancer with those of participants who had changes in VOC levels considered to be precancerous, the scientists identified eight distinctive "breath-print" compositions.

On applying the nanoarray technique to the breath samples, the team found it was effectively able to distinguish between breath-print compositions in participants with stomach cancer and those at low and high risk of the condition. The method achieved 73% sensitivity, 98% specificity and 92% accuracy, according to the results. While GCMS technology is unable to be used for stomach cancer screening due to its high cost and complexity, the scientists say nanoarray analysis may be a highly accurate and cheaper alternative. The study was published on April 13, 2015, in the journal Gut.

Related Links:

Israel Institute of Technology



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.